Tangential Flow Filtration Explained: How Single-Use and Single-Pass Formats Streamline Biologics Purification

Tangential Flow Filtration Process Flow

Tangential Flow Filtration sweeps feed across a membrane instead of pushing it through, cutting clogging and shear stress. This guide covers ultrafiltration, diafiltration, single-use and single-pass formats, and limits.

LOTTE Biologics Songdo Plant 1 Lands First Major Commercial Manufacturing Agreement Ahead of Launch

Lotte Biologics News

LOTTE Biologics Songdo Plant 1 has secured its first major commercial manufacturing agreement with a global pharmaceutical company ahead of its operational launch. The deal covers integrated drug substance and drug product manufacturing, with commercial production targeted for 2027.

Pfizer Starna Licensing Agreement: Pfizer Secures Exclusive In Vivo CAR-T Rights for Autoimmune Diseases in $330 Million Upfront Deal

pfizer news

The Pfizer Starna licensing agreement hands Pfizer exclusive rights outside Greater China to three pre-IND in vivo CAR-T autoimmune programs, backed by a $330 million upfront payment and up to $2.3 billion in milestones.

Johnson & Johnson Announces $2.2 Billion Ollin Biosciences Acquisition to Add Phase 3 Eye Antibody OLN324

Johnson & Johnson Company Information

Johnson & Johnson has agreed to acquire Ollin Biosciences for $2.2 billion upfront, adding the Phase 3 bispecific antibody OLN324 for wet AMD and diabetic macular edema. A separate $750 million Blackstone Life Sciences funding agreement would support Phase 3 development.

FDA Rejected Ivonescimab: Summit Therapeutics Receives Complete Response Letter for NSCLC BLA Based on HARMONi Study

US FDA News

The FDA rejected ivonescimab in its present form, issuing a Complete Response Letter for Summit Therapeutics’ NSCLC BLA. The agency said a PFS benefit without significant overall survival does not establish substantial evidence of effectiveness.

Novo Nordisk CagriSema REDEFINE 9 Trial Shows ~21% Average Weight Loss at Lower Doses at ObesityWeek 2026

Novo Nordisk new logo Novo

Novo Nordisk’s phase 3 CagriSema REDEFINE 9 trial showed estimated average weight loss of 20.7% and 21.0% at 68 weeks with lower CagriSema doses, versus 2.0% with placebo. Results were presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology.